Content area

|
|

Hæmning af proteinet PCSK9 er en lovende behandling af hyperkolesterolæmi og forebyggelse af hjerte-kar-sygdom

Forfatter(e)
Morten Krogh Christiansen & Henrik Kjærulf Jensen Afdeling for Hjerte-sygdomme, Aarhus Universitetshospital Ugeskr Læger 2015;177:V11140582
Reference: 
Ugeskr Læger 2015;177:V11140582
Blad nummer: 
Sidetal: 
2-5
Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease
Recent research in genetics has revealed that PCSK9 – which codes for proprotein convertase subtilisin/kexin type 9 (PCSK9) – plays a major role in cholesterol regulatory pathways. Normal genetic variations in PCSK9 have a great impact on low-density lipoprotein cholesterol levels and hence the risk of cardio-vascular disease. This has led to huge efforts in inhibiting PCSK9. Recent clinical phase II trials with monoclonal antibodies against PCSK9 have shown great results for lowering low-density lipoprotein cholesterol levels making the inhibition of PCSK9 a promising target in the prevention of cardiovascular disease.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Gert Einar Storm Kristensen | 20/11
1 Kommentar
af Finn Olav Hansen | 20/11
10 kommentarer
af Svend Erik Gundestrup | 19/11
12 kommentarer
af Anders Mark Christensen | 19/11
1 Kommentar
af Jens Meyer Svendsen | 17/11
1 Kommentar
af Peter Søndergaard | 17/11
1 Kommentar
af Tom Nygaard Kristensen | 16/11
1 Kommentar
af Susanne Udengaard Gydesen | 16/11
6 kommentarer
af Lars Otto Hutters | 16/11
2 kommentarer